93Indexed trials
Market Rank #32 · Evidence Tier A
Russia
Neuroscience Intelligence
Russia neuroscience intelligence: 93 indexed trials, 19 institutions, research score 28.83.
9Recruiting
19Research institutions
28.8Research score
Evidence profile
47Sponsors
19Disease areas
0Institution works
0Institution citations
Model signals
Opportunity 29 · ML priority 29 · Confidence 85 · Evidence 28.8
These are comparative evidence signals. They do not represent a guarantee of market size or commercial outcome.
Leading disease areas
parkinsons14trials
epilepsy11trials
alzheimers11trials
depression8trials
stroke7trials
neuromuscular4trials
schizophrenia4trials
bipolar_disorder4trials
multiple_sclerosis4trials
other_neurology3trials
Leading indexed sponsors
Hoffmann-La Roche11trials
Merck Sharp & Dohme LLC9trials
Pfizer5trials
Eli Lilly and Company5trials
Sumitomo Pharma America, Inc.5trials
GlaxoSmithKline4trials
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3trials
Boehringer Ingelheim3trials
Novo Nordisk A/S3trials
AbbVie2trials